PharmiWeb.com - Global Pharma News & Resources
17-Jan-2019

CIO Bulletin Announces DiaCarta Inc. As One of the 30 Fastest Growing Companies of 2018

DiaCarta today announced that CIO Bulletin has named it among the 30 Fastest Growing Companies of 2018. The positioning is based on DiaCarta’s revenue growth, financial status, openness to innovation, global collaboration and partnership, flagship products launching, regulatory progress and ability to forecast future business and technology trends. Selecting by a panel of experts and members of CIO Bulletin’s editorial board, the CIO Bulletin 30 Fastest Growing Companies of 2018 is a premier recognition program which identifies companies that have the most innovative approach towards understanding the market trends and exceptional problem-solving techniques in the field of Business and Technology.

“We are glad to name DiaCarta as one of the 30 fastest growing companies of 2018. Realizing a total of $45.0 M USD through its Series B funding round, DiaCarta has made several milestones in the year of 2018 for its development and commercialization of the precision molecular diagnostics products (CE only), including liquid biopsy single gene mutation detection tests, colorectal cancer mutation detection blood test, blood-based radiation therapy toxicity monitoring test, HPV mRNA test, etc. and all the clinical developments,” said J. P. Pande, Editor-in-Chief of the CIO Bulletin Magazine.

“We are honored and thrilled to be recognized by CIO Bulletin as one of the 30 Fastest Growing Companies of 2018,” said Aiguo (Adam) Zhang, CEO and Founder of DiaCarta, “We are moving our business to the next level by putting our flagship products to clinical trials in the U.S., China, and Italy in 2019 and looking forward to serving cancer diagnostic and therapeutic community with our innovations that redefine precision molecular diagnostics.”

ABOUT DIACARTA

DiaCarta is a translational genomics and personalized diagnostics company based in Richmond, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies in molecular diagnostics and clinical genomics. With over 20,000 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, DiaCarta is changing the landscape of molecular diagnostics.

ABOUT CIO BULLETIN

CIO Bulletin is an interactive, preeminent leadership platform serving as a central resource for information on Business & Information Technology (IT) leaders and their entrepreneurial ventures. From celebrating innovation to identifying best practices and providing a forum for today’s CIOs and other technology decision makers, CIO Bulletin aspires to keep its readers informed about how the techie giants, governments and consumers are unfurling organizational innovation in the Business & IT world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190117005020/en/

Editor Details

Last Updated: 17-Jan-2019